The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2024-04-30), ADMA Biologics's share price is $6.52. ADMA Biologics's Book Value per Share for the quarter that ended in Dec. 2023 was $0.60. Hence, ADMA Biologics's PB Ratio of today is 10.90.
Warning Sign:
ADMA Biologics Inc stock PB Ratio (=11) is close to 3-year high of 11.04
The historical rank and industry rank for ADMA Biologics's PB Ratio or its related term are showing as below:
ADMA'
s PB Ratio Range Over the Past 10 Years
Min: 1.41 Med: 5.62 Max: 104.81
Current: 10.87
During the past 13 years, ADMA Biologics's highest PB Ratio was 104.81. The lowest was 1.41. And the median was 5.62.
ADMA's PB Ratio is ranked worse than 90.9% of 1308
companies
in the Biotechnology industry
Industry Median: 2.435
vs ADMA: 10.87
During the past 12 months, ADMA Biologics's average Book Value Per Share Growth Rate was -12.70% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was -10.70% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was 8.50% per year.
During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of ADMA Biologics was 77.00% per year. The lowest was -66.40% per year. And the median was 11.20% per year.
Back to Basics: PB Ratio
ADMA Biologics PB Ratio Historical Data
The historical data trend for ADMA Biologics's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of ADMA Biologics's PB Ratio
For the Biotechnology subindustry, ADMA Biologics's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
ADMA Biologics's PB Ratio Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, ADMA Biologics's PB Ratio distribution charts can be found below:
* The bar in red indicates where ADMA Biologics's PB Ratio falls into.
ADMA Biologics PB Ratio Calculation
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
ADMA Biologics's PB Ratio for today is calculated as follows:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
ADMA Biologics PB Ratio Related Terms
Thank you for viewing the detailed overview of ADMA Biologics's PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.
ADMA Biologics (ADMA Biologics) Business Description
ADMA Biologics Inc is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. Its targeted patient populations include immune-compromised individuals who suffer from an underlying immune deficiency disorder or who may be immune-suppressed for medical reasons. The company sells plasma-derived intermediate fractions to certain customers, which are generated as part of its FDA-approved manufacturing process for IG and IVIG products. It also provides laboratory contracting services to certain customers and anticipates providing contract filling, labeling and packing services.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
ADMA has been successfully added to your 